FDA Reviewing Chantix Postmarketing Data On Suicide, Erratic Behavior
This article was originally published in The Pink Sheet Daily
Executive Summary
Early communication by the agency follows one case of erratic behavior leading to the death of a patient using the smoking cessation drug.
You may also be interested in...
Pfizer's Pitch For Chantix Warning Reduction Focuses On Those With Mental Illness
Those patients need more options for smoking cessation, Pfizer says, but that is the group FDA most worries about when deciding whether to remove its boxed warning.
Pfizer's Chantix Warning May Remain As FDA Raises Trial Concerns
FDA will present concerns on data collection and study conduct during advisory committee meeting on removing smoking cessation drug's boxed warning.
FDA’s Black Box Instant Replay: A Higher Standard To Remove
Pfizer’s request for leniency on Chantix will likely be shelved, but advisory committee allows exploration of regulatory area where FDA has limited experience: The rollback of safety labeling.